US 12,655,219 B2Granted

Anti-CTLA-4 antibody and use thereof

AssigneeShanghai Junshi Biosciences Co., Ltd.

InventorsZhiwei Pan, Jian Yao, Jing Zhang, Yuehua Zhou, Hongchuan Liu, Hai Wu, Sheng Yao, Hui Feng

Life of this patent

Estimating the term…

Abstract

An antibody specifically binding to CTLA-4 or an antigen-binding fragment thereof, and a composition comprising same. Also provided are a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a vector and a host cell for expressing the antibody or an antigen-binding fragment thereof, and therapeutic and diagnostic methods and the use of the antibody or an antigen-binding fragment thereof.

Claims17

Dependent claims

An anti-CTLA-4 antibody or an antigen-binding fragment thereof, comprising:

(I) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
1, SEQ ID NO:
2 and SEQ ID NO:
3, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
4, SEQ ID NO:
5 and SEQ ID NO:
6, respectively;
or
(II) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
7, SEQ ID NO:
8 and SEQ ID NO:
9, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
10, SEQ ID NO:
11 and SEQ ID NO:
12, respectively;
or
(III) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
13, SEQ ID NO:
14 and SEQ ID NO:
15, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
16, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(IV) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
19, SEQ ID NO:
20 and SEQ ID NO:
21, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
16, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(V) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
22, SEQ ID NO:
23 and SEQ ID NO:
24, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
25, SEQ ID NO:
26 and SEQ ID NO:
27, respectively;
or
(VI) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
1, SEQ ID NO:
2 and SEQ ID NO:
3, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
16, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(VII) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
19, SEQ ID NO:
39 and SEQ ID NO:
21, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
40, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(VIII) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
1, SEQ ID NO:
37 and SEQ ID NO:
38, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
40, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(IX) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
19, SEQ ID NO:
20 and SEQ ID NO:
21, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
40, SEQ ID NO:
17 and SEQ ID NO:
18, respectively.

77 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

An anti-CTLA-4 antibody or an antigen-binding fragment thereof, comprising:

(I) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
1, SEQ ID NO:
2 and SEQ ID NO:
3, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
4, SEQ ID NO:
5 and SEQ ID NO:
6, respectively;
or
(II) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
7, SEQ ID NO:
8 and SEQ ID NO:
9, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
10, SEQ ID NO:
11 and SEQ ID NO:
12, respectively;
or
(III) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
13, SEQ ID NO:
14 and SEQ ID NO:
15, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
16, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(IV) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
19, SEQ ID NO:
20 and SEQ ID NO:
21, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
16, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(V) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
22, SEQ ID NO:
23 and SEQ ID NO:
24, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
25, SEQ ID NO:
26 and SEQ ID NO:
27, respectively;
or
(VI) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
1, SEQ ID NO:
2 and SEQ ID NO:
3, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
16, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(VII) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
19, SEQ ID NO:
39 and SEQ ID NO:
21, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
40, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(VIII) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
1, SEQ ID NO:
37 and SEQ ID NO:
38, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
40, SEQ ID NO:
17 and SEQ ID NO:
18, respectively;
or
(IX) a heavy chain variable region, comprising HCDR1, HCDR2, and HCDR3 whose amino acid sequences are set forth in SEQ ID NO:
19, SEQ ID NO:
20 and SEQ ID NO:
21, respectively;
and a light chain variable region, comprising LCDR1, LCDR2, and LCDR3 whose amino acid sequences are set forth in SEQ ID NO:
40, SEQ ID NO:
17 and SEQ ID NO:
18, respectively.

77 more elements